Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ischemix names Robert DuFresne CEO

This article was originally published in Scrip

Executive Summary

Ischemix, a US biotechnology company developing compounds to reduce and/or prevent cell and organ damage associated with ischaemia-reperfusion injury caused by cardiac surgery, heart attack and stenting procedures, has named Robert DuFresne chief executive officer. The company's former CEO, Dr Reinier Beeuwkes, will continue to serve as president and chairman. Mr DuFresne has more than 25 years' experience in the biopharmaceutical industry, having most recently worked as president and CEO of Pacgen Biopharmaceuticals. He has served on Ischemix's board of directors since May 2007, a role in which he will continue.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC001167

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel